Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1948 1
1963 1
1964 2
1965 2
1966 3
1967 3
1969 2
1970 3
1972 1
1974 2
1976 1
1977 3
1978 2
1980 4
1981 3
1982 7
1983 3
1984 6
1985 6
1986 9
1987 5
1988 4
1989 8
1990 8
1991 19
1992 8
1993 15
1994 5
1995 19
1996 15
1997 12
1998 13
1999 12
2000 12
2001 14
2002 16
2003 28
2004 17
2005 22
2006 23
2007 21
2008 30
2009 30
2010 34
2011 36
2012 33
2013 50
2014 56
2015 53
2016 37
2017 59
2018 48
2019 51
2020 59
2021 65
2022 54
2023 52
2024 55
2025 36

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,080 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. Among authors: quinn di. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. N Engl J Med. 2021. PMID: 34407342 Free article. Clinical Trial.
A Neural Circuit for Gut-Induced Reward.
Han W, Tellez LA, Perkins MH, Perez IO, Qu T, Ferreira J, Ferreira TL, Quinn D, Liu ZW, Gao XB, Kaelberer MM, Bohórquez DV, Shammah-Lagnado SJ, de Lartigue G, de Araujo IE. Han W, et al. Among authors: quinn d. Cell. 2018 Oct 18;175(3):665-678.e23. doi: 10.1016/j.cell.2018.08.049. Epub 2018 Sep 20. Cell. 2018. PMID: 30245012 Free PMC article.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators. Bellmunt J, et al. Among authors: quinn di. N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17. N Engl J Med. 2017. PMID: 28212060 Free PMC article. Clinical Trial.
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.
Rosenberg J, Sridhar SS, Zhang J, Smith D, Ruether D, Flaig TW, Baranda J, Lang J, Plimack ER, Sangha R, Heath EI, Merchan J, Quinn DI, Srinivas S, Milowsky M, Wu C, Gartner EM, Zuo P, Melhem-Bertrandt A, Petrylak DP. Rosenberg J, et al. Among authors: quinn di. J Clin Oncol. 2020 Apr 1;38(10):1041-1049. doi: 10.1200/JCO.19.02044. Epub 2020 Feb 7. J Clin Oncol. 2020. PMID: 32031899 Free PMC article. Clinical Trial.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Among authors: quinn di. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9. Lancet Oncol. 2022. PMID: 36055304 Free article. Clinical Trial.
Reply by Authors.
Mitra AP, Cai J, Miranda G, Bhanvadia S, Quinn DI, Schuckman AK, Djaladat H, Daneshmand S. Mitra AP, et al. Among authors: quinn di. J Urol. 2022 Feb;207(2):313. doi: 10.1097/JU.0000000000002242.02. Epub 2021 Nov 8. J Urol. 2022. PMID: 34994654 No abstract available.
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY, Petrylak DP, O'Donnell PH, Lee JL, van der Heijden MS, Loriot Y, Stein MN, Necchi A, Kojima T, Harrison MR, Hoon Park S, Quinn DI, Heath EI, Rosenberg JE, Steinberg J, Liang SY, Trowbridge J, Campbell M, McGregor B, Balar AV. Yu EY, et al. Among authors: quinn di. Lancet Oncol. 2021 Jun;22(6):872-882. doi: 10.1016/S1470-2045(21)00094-2. Epub 2021 May 12. Lancet Oncol. 2021. PMID: 33991512 Clinical Trial.
Gastroenterology.
Quinn DN, Pfeil SA. Quinn DN, et al. Clin Podiatr Med Surg. 2002 Jan;19(1):23-42. doi: 10.1016/S0891-8422(03)00079-X. Clin Podiatr Med Surg. 2002. PMID: 11806164 Review.
Concussion.
Master CL, Mayer AR, Quinn D, Grady MF. Master CL, et al. Among authors: quinn d. Ann Intern Med. 2018 Jul 3;169(1):ITC1-ITC16. doi: 10.7326/AITC201807030. Ann Intern Med. 2018. PMID: 29971425 Review.
A Neural Circuit for Gut-Induced Reward.
Han W, Tellez LA, Perkins MH, Perez IO, Qu T, Ferreira J, Ferreira TL, Quinn D, Liu ZW, Gao XB, Kaelberer MM, Bohórquez DV, Shammah-Lagnado SJ, de Lartigue G, de Araujo IE. Han W, et al. Among authors: quinn d. Cell. 2018 Oct 18;175(3):887-888. doi: 10.1016/j.cell.2018.10.018. Cell. 2018. PMID: 30340046 Free article. No abstract available.
1,080 results